Non-Alcoholic Fatty Liver Disease - A Practical Guide

List of Contributors, vii 1 What is non-alcoholic fatty liver disease (NAFLD), and why is it important? 1 Geoffrey C. Farrell, Arthur J. McCullough, and Christopher P. Day 2 NAFLD in the community, 17 Leon A. Adams 3 Pathology of NAFLD, 27 Elizabeth M. Brunt and David E. Kleiner 4 The natural history of NAFLD, 37 Paul Angulo 5 Emerging concepts on the pathogenesis of non-alcoholic steatohepatitis (NASH), 46 Isabelle A. Leclercq 6 Diabetes and NAFLD: why is the connection important? 62 Elisabetta Bugianesi 7 NAFLD and cardiovascular risk factors: implications for vascular disease, 71 Giovanni Targher 8 A primary care perspective of fatty liver: diagnosis, management, prescribing, and when to refer, 84 Shivakumar Chitturi and Geoffrey C. Farrell 9 Imaging of NAFLD, 93 Takeshi Yokoo, An Tang, and Claude B. Sirlin 10 Non-invasive methods to determine the severity of NAFLD and NASH, 112 Vincent Wai-Sun Wong and Henry Lik-Yuen Chan 11 Fatigue, quality of life, and psychosocial issues for people with NAFLD, 122 Julia L. Newton and James Frith 12 Physical activity and cardiovascular fi tness in patients with NAFLD: clinical importance and therapeutic implications, 132 Ingrid J. Hickman, Graeme A. Macdonald, and Nuala M. Byrne 13 NAFLD, obesity, and bariatric surgery, 149 Philippe Mathurin 14 Genetic predisposition to NAFLD and NASH: implications for pathogenesis, diagnosis, prevention, and management, 157 Quentin M. Anstee, Ann K. Daly, and Christopher P. Day 15 NAFLD in children, 171 Ariel E. Feldstein 16 The pointy end of the NAFLD iceberg: cirrhosis, portal hypertension, and liver failure, 182 Jonathon W. Schwake, Dawn M. Torres, and Stephen A. Harrison 17 Non-alcoholic fatty liver disease, hepatocellular cancer, and other cancers, 192 Janine Graham and Helen L. Reeves 18 NAFLD in Chinese and South Asian people, 206 Jia-Horng Kao, Deepak Amarapurkar, and Jian-Gao Fan 19 Non-alcoholic fatty liver disease in Japan, 217 Takeshi Okanoue, Kohichiroh Yasui, and Yoshito Itoh 20 Non-alcoholic fatty liver disease in South America and Hispanic people, 228 Helma Pinchemel Cotrim and Carla Daltro 21 Alcohol in non-alcoholic fatty liver disease: an oxymoron or a new standard of care?, 234 Achuthan Sourianarayanane, Srinivasan Dasarathy, and Arthur J. McCullough 22 Dietary factors in the pathogenesis and care of patients with fatty liver disease, 248 Giulio Marchesini, Rebecca Marzocchi, Anna S. Sasdelli, Cristiana Andruccioli, and Silvia Di Domizio 23 Metabolic factors and steatosis in patients with hepatitis B and C, 260 Francesco Negro 24 Drug therapy for NASH: insulin-sensitizing agents (metformin and thiazolidinediones), 271 Mohammad S. Siddiqui and Arun J. Sanyal 25 Hepatoprotectants against fatty liver disease: antioxidants, ursodeoxycholic acid, and herbal medicines, 284 Anne Catherine Burgi and Jean-Francois Dufour 26 Lipid modifiers and NASH: statins, ezetimibe, fibrates, and other agents, 293 Giovanni Musso, Federica Molinaro, Elena Paschetta, Roberto Gambino, and Maurizio Cassader Index, 308 Color plate section facing p86